Literature DB >> 25449311

Ovarian cancer in the United States: contemporary patterns of care associated with improved survival.

William A Cliby1, Matthew A Powell2, Noor Al-Hammadi3, Ling Chen3, J Philip Miller3, Phillip Y Roland4, David G Mutch2, Robert E Bristow5.   

Abstract

BACKGROUND: Ovarian cancer (OC) requires complex multidisciplinary care with wide variations in outcome. We sought to determine the impact of institutional and process of care factors on overall survival (OS) and delivery of guideline care nationally.
METHODS: This was a retrospective cohort study of primary OC diagnosed from 1998 to 2007 using the National Cancer Data Base (NCDB) capturing 80% of all U.S. cases. Patient- (demographics, comorbidities, stage/grade), process of care (adherence to guidelines) and institutional- (facility type, case volume) factors were evaluated. Primary outcomes were OS and delivery of guideline therapy. Multivariable logistic regression and Cox proportional hazards models were used for analysis.
RESULTS: We analyzed 96,802 consecutive cases. Five-year OS was 84%, 66.3%, 32% and 15.7% for stages I, II, III and IV, respectively. The annual mean facility case volumes varied by cancer center type (range: 5.7 to 26.7), with 25% of cases spread over 65% of centers--all treating fewer than 8 cases. Overall, 56% of cases received non-guideline care. Low facility case volume and higher comorbidity index independently predicted non-guideline care; high volume centers were less likely to deliver non-guideline care (OR: 0.44, 95% CI: 0.41-0.47). Delivery of non-guideline care (OR: 1.4, 95% CI: 1.36-1.44), and higher facility case volume (OR: 0.91, 95% CI: 0.86-0.96) were both independent predictors of OS.
CONCLUSIONS: Delivery of guideline care and facility case volume are important drivers of overall survival. Most cancer centers treat very few women with OC. National efforts should focus on improved access to centers with expertise in OC and ensuring delivery of guideline care.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer center; Care patterns; Ovarian cancer; Survival; United States; Volume

Mesh:

Year:  2014        PMID: 25449311      PMCID: PMC4419829          DOI: 10.1016/j.ygyno.2014.10.023

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  22 in total

1.  FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics.

Authors:  S Pecorelli; J L Benedet; W T Creasman; J H Shepherd
Journal:  Int J Gynaecol Obstet       Date:  1999-06       Impact factor: 3.561

2.  Influence of hospital procedure volume on ovarian cancer survival in Japan, a country with low incidence of ovarian cancer.

Authors:  Akiko Ioka; Hideaki Tsukuma; Wakiko Ajiki; Akira Oshima
Journal:  Cancer Sci       Date:  2004-03       Impact factor: 6.716

3.  Ovarian cancer: patterns of surgical care across the United States.

Authors:  Barbara A Goff; Barbara J Matthews; Michelle Wynn; Howard G Muntz; Denise M Lishner; Laura-Mae Baldwin
Journal:  Gynecol Oncol       Date:  2006-09-26       Impact factor: 5.482

4.  The National Cancer Data Base report on ovarian cancer treatment in United States hospitals.

Authors:  E E Partridge; J L Phillips; H R Menck
Journal:  Cancer       Date:  1996-11-15       Impact factor: 6.860

5.  Trends in surgery and chemotherapy for women diagnosed with ovarian cancer in the United States.

Authors:  Linda C Harlan; Limin X Clegg; Edward L Trimble
Journal:  J Clin Oncol       Date:  2003-09-15       Impact factor: 44.544

Review 6.  Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review.

Authors:  Andreas du Bois; Justine Rochon; Jacobus Pfisterer; William J Hoskins
Journal:  Gynecol Oncol       Date:  2008-11-06       Impact factor: 5.482

7.  Impact of hospital volume on operative mortality for major cancer surgery.

Authors:  C B Begg; L D Cramer; W J Hoskins; M F Brennan
Journal:  JAMA       Date:  1998-11-25       Impact factor: 56.272

8.  The effect of centralization of primary surgery on survival in ovarian cancer patients.

Authors:  Solveig Tingulstad; Finn Egil Skjeldestad; Bjørn Hagen
Journal:  Obstet Gynecol       Date:  2003-09       Impact factor: 7.661

9.  Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals.

Authors:  T Paulsen; K Kjaerheim; J Kaern; S Tretli; C Tropé
Journal:  Int J Gynecol Cancer       Date:  2006 Jan-Feb       Impact factor: 3.437

10.  Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades.

Authors:  Jill S Barnholtz-Sloan; Ann G Schwartz; Faisal Qureshi; Suzanne Jacques; John Malone; Adnan R Munkarah
Journal:  Am J Obstet Gynecol       Date:  2003-10       Impact factor: 8.661

View more
  47 in total

1.  Potential Consequences of Minimum-Volume Standards for Hospitals Treating Women With Ovarian Cancer.

Authors:  Jason D Wright; Yongmei Huang; Alexander Melamed; Ana I Tergas; Caryn M St Clair; June Y Hou; Fady Khoury-Collado; Cande V Ananth; Alfred I Neugut; Dawn L Hershman
Journal:  Obstet Gynecol       Date:  2019-06       Impact factor: 7.661

Review 2.  Is It Time to Centralize Ovarian Cancer Care in the United States?

Authors:  Renee A Cowan; Roisin E O'Cearbhaill; Ginger J Gardner; Douglas A Levine; Kara Long Roche; Yukio Sonoda; Oliver Zivanovic; William P Tew; Evis Sala; Yulia Lakhman; Hebert A Vargas Alvarez; Debra M Sarasohn; Svetlana Mironov; Nadeem R Abu-Rustum; Dennis S Chi
Journal:  Ann Surg Oncol       Date:  2015-10-28       Impact factor: 5.344

3.  Evaluation of determinants for age disparities in the survival improvement of colon cancer: results from a cohort of more than 486,000 patients in the United States.

Authors:  Fa Chen; Fei Wang; Christina E Bailey; Harvey J Murff; Jordan D Berlin; Xiao-Ou Shu; Wei Zheng
Journal:  Am J Cancer Res       Date:  2020-10-01       Impact factor: 6.166

4.  Disparities in ovarian cancer survival in the United States (2001-2009): Findings from the CONCORD-2 study.

Authors:  Sherri L Stewart; Rhea Harewood; Melissa Matz; Sun Hee Rim; Susan A Sabatino; Kevin C Ward; Hannah K Weir
Journal:  Cancer       Date:  2017-12-15       Impact factor: 6.860

5.  Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer.

Authors:  Larissa A Meyer; Angel M Cronin; Charlotte C Sun; Kristin Bixel; Michael A Bookman; Mihaela C Cristea; Jennifer J Griggs; Charles F Levenback; Robert A Burger; Gina Mantia-Smaldone; Ursula A Matulonis; Joyce C Niland; David M O'Malley; Alexi A Wright
Journal:  J Clin Oncol       Date:  2016-11-10       Impact factor: 44.544

6.  Improved anti-tumor efficacy of paclitaxel in combination with MicroRNA-125b-based tumor-associated macrophage repolarization in epithelial ovarian cancer.

Authors:  Neha N Parayath; Srujan Kumar Gandham; Fraser Leslie; Mansoor M Amiji
Journal:  Cancer Lett       Date:  2019-07-06       Impact factor: 8.679

7.  Variation in neoadjuvant chemotherapy utilization for epithelial ovarian cancer at high volume hospitals in the United States and associated survival.

Authors:  Emma L Barber; Stacie B Dusetzina; Karyn B Stitzenberg; Emma C Rossi; Paola A Gehrig; John F Boggess; Joanne M Garrett
Journal:  Gynecol Oncol       Date:  2017-03-31       Impact factor: 5.482

8.  Cancer and treatment-related symptoms are associated with mobility disability in women with ovarian cancer: A cross-sectional study.

Authors:  Grace Campbell; Teresa Hagan; Stephanie Gilbertson-White; Martin Houze; Heidi Donovan
Journal:  Gynecol Oncol       Date:  2016-09-18       Impact factor: 5.482

9.  Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Alexi A Wright; Kari Bohlke; Deborah K Armstrong; Michael A Bookman; William A Cliby; Robert L Coleman; Don S Dizon; Joseph J Kash; Larissa A Meyer; Kathleen N Moore; Alexander B Olawaiye; Jessica Oldham; Ritu Salani; Dee Sparacio; William P Tew; Ignace Vergote; Mitchell I Edelson
Journal:  Gynecol Oncol       Date:  2016-08-08       Impact factor: 5.482

10.  Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Alexi A Wright; Kari Bohlke; Deborah K Armstrong; Michael A Bookman; William A Cliby; Robert L Coleman; Don S Dizon; Joseph J Kash; Larissa A Meyer; Kathleen N Moore; Alexander B Olawaiye; Jessica Oldham; Ritu Salani; Dee Sparacio; William P Tew; Ignace Vergote; Mitchell I Edelson
Journal:  J Clin Oncol       Date:  2016-08-08       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.